Mounting evidence has demonstrated that the cGAS-STING pathway plays an important regulatory role in all stages of the cancer-immunity cycle, either activating or suppressing anti-tumor immune responses, depending on the strength and timing of the activation of the cGAS-STING pathway and the type and state of the tumors (14, 25–27). This evidence concerns the gene STING1 and cancer.